Screening/Prevention
Liquid-based Cytology No More Accurate than Conventional Pap Test for Cervical Screening
(01/03/2008)
For the detection of cervical abnormalities, liquid-based cytology does not appear to be more accurate than the conventional Pap test. This was the conclusion of a combined analysis published in the journal Obstetrics and Gynecology.
Increased Risk of Cervical Cancer with Oral Contraceptive Use
(11/14/2007)
According to an article recently published in The Lancet, the use of combined oral contraceptives (estrogen and progestin) temporarily increases the risk of cervical cancer. However, this risk remains small: one extra person per 1,000 is diagnosed with cervical cancer with use of the contraceptives.
Increased Risk of Cancer Persists Long After Treatment for Precancerous Cervical Changes
(11/07/2007)
According to the results of a study published in the British Medical Journal, women who have been treated for high-grade precancerous changes to the cervix (cervical intraepithelial neoplasia grade 3) are more likely than women in the general population to subsequently develop cervical or vaginal cancer. Furthermore, this increased risk persists for at least 25 years.
HPV Testing Detects Greater Number of Cervical Abnormalities
(10/18/2007)
According to the results of a study published in the New England Journal of Medicine, testing for high-risk types of human papillomavirus (HPV) detects a higher proportion of precancerous changes to the cervix than conventional Pap testing, but also produces more false-positive results. A second study published in the same issue assessed the combination of HPV testing and Pap testing.
HPV Vaccine Does Not Treat Existing Infections
(08/24/2007)
According to the results of a study published in the Journal of the American Medical Association, Cervarix™—a vaccine designed to prevent infection with two high-risk types of human papillomavirus (HPV)—does not treat HPV infections in women who are already infected at the time of vaccination.
More...
Stage I
Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers
(03/31/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in gynecological cancers difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
PET Scans May Prove Useful for Predicting Cervical Cancer Outcome
(11/27/2007)
According to the results of a study published in the Journal of the American Medical Association, post-treatment imaging with positron emission tomography (PET) may provide important information about response to cervical cancer treatment and likelihood of survival.
Cervical Cancer Survivors Face Long-term Risk of Second Cancers
(11/01/2007)
According to the results of a study published in the Journal of the National Cancer Institute, cervical cancer survivors have an increased risk of later developing other types of cancer, particularly if their cervical cancer was treated with radiation therapy. This increased risk persists for more than 40 years after the cervical cancer diagnosis.
Expanded Indications for Fertility-preserving Surgery for Early Cervical Cancer
(08/07/2007)
The National Comprehensive Cancer Network (NCCN) has recommended fertility-preserving surgery to include more women with cervical cancer.
Cervical Cancer Survivors Face Risk of Second Cancers
(04/27/2007)
According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), the risk of a second cancer among women with a history of cervical cancer is higher than the cancer risk in the general population.
More...
Stages II-IVA
Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers
(03/31/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in gynecological cancers difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
PET Scans May Prove Useful for Predicting Cervical Cancer Outcome
(11/27/2007)
According to the results of a study published in the Journal of the American Medical Association, post-treatment imaging with positron emission tomography (PET) may provide important information about response to cervical cancer treatment and likelihood of survival.
Cervical Cancer Survivors Face Long-term Risk of Second Cancers
(11/01/2007)
According to the results of a study published in the Journal of the National Cancer Institute, cervical cancer survivors have an increased risk of later developing other types of cancer, particularly if their cervical cancer was treated with radiation therapy. This increased risk persists for more than 40 years after the cervical cancer diagnosis.
Cervical Cancer Survivors Face Risk of Second Cancers
(04/27/2007)
According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), the risk of a second cancer among women with a history of cervical cancer is higher than the cancer risk in the general population.
HPV in Lymph Nodes and Cervical Cancer Spread to Lymph Nodes Have Same Outcomes
(03/30/2007)
According to an article recently published in Gynecologic Oncology, outcomes among patients with cervical cancer who had human papillomavirus (HPV) found in nearby lymph nodes were similar to those whose cancer had spread to the lymph nodes.
More...
Metastatic/Stage IVB
Cervical Cancer Survivors Face Risk of Second Cancers
(04/27/2007)
According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), the risk of a second cancer among women with a history of cervical cancer is higher than the cancer risk in the general population.
Hycamtin® Approved for Advanced Cervical Cancer
(06/26/2006)
According to a press release from GlaxoSmithKline, Hycamtin® (topotecan) was recently approved by the U.S. Food and Drug Administration (FDA) for a new use—the treatment of stage IVB, recurrent, or persistent cervical cancer, when given in combination with Platinol® (cisplatin).
Combination of Cisplatin and Topotecan Improves Survival in Advanced Cervical Cancer
(07/28/2005)
A phase III clinical trial published in the Journal of Clinical Oncology reported that women with advanced cervical cancer treated with a combination of cisplatin (Platinol®) plus topotecan (Hycamtin®) chemotherapy lived longer than women treated with cisplatin alone.
Stress and Depression Frequent Among Women Treated for Gynecological Cancers
(02/22/2005)
According to the results of a study recently published in Gynecologic Oncology, women with gynecologic cancer often experience emotional stress and depression after losing their fertility from cancer treatment.
Addition of Taxol(R) to Cisplatin Improves Progression-Free Survival in Advanced Cervical Cancer
(08/04/2004)
According to a recent article published in the Journal of Clinical Oncology, the addition of Taxol® (paclitaxel) to cisplatin (Platinol®) improves survival in patients with advanced cervical cancer.
More...
Recurrent
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers
(03/17/2008)
The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Cervical Cancer Survivors Face Long-term Risk of Second Cancers
(11/01/2007)
According to the results of a study published in the Journal of the National Cancer Institute, cervical cancer survivors have an increased risk of later developing other types of cancer, particularly if their cervical cancer was treated with radiation therapy. This increased risk persists for more than 40 years after the cervical cancer diagnosis.
Cervical Cancer Survivors Face Risk of Second Cancers
(04/27/2007)
According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), the risk of a second cancer among women with a history of cervical cancer is higher than the cancer risk in the general population.
Possible Role for Avastin® in Recurrent Cervical Cancer
(11/15/2006)
A small study of six patients suggests that the combination of Avastin® (bevacizumab) and chemotherapy may be a promising approach to the treatment of recurrent cervical cancer. These results were published in the journal Gynecologic Oncology.
Stress and Depression Frequent Among Women Treated for Gynecological Cancers
(02/22/2005)
According to the results of a study recently published in Gynecologic Oncology, women with gynecologic cancer often experience emotional stress and depression after losing their fertility from cancer treatment.
More...